Programs & products

Preliminary results of IPH5401 STELLAR-001, a dose escalation Phase I study in patients with advanced solid tumors 1-year survival data of monalizumab in combination with cetuximab in h ead and neck...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), today announced that it will host a key opinion leader (KOL) call focused on the topic of IPH4102 “TELLOMAK” clinical trial...

TELLOMAK is a Phase II study to evaluate the efficacy of IPH4102 in different subtypes of T-cell lymphoma The TELLOMAK trial design and preclinical data in PTCL will be presented at the International...

Differentiating profile of IPH4102 confirmed: high and durable response, favorable safety profile with long-term follow-up and substantial improvement in quality of life Innate Pharma expects to...

Monalizumab is a first-in-class broad-spectrum immune checkpoint inhibitor with a dual effect on both Natural Killer (NK) cells and T lymphocytes Monalizumab showed promising preclinical and clinical...

These data support the advancement of the clinical program, starting with the enrollment of an additional cohort of patients who received both prior platinum-based chemotherapy and PD-1/L1 inhibitors...

Innate Pharma acquires US and EU rights to commercialize Lumoxiti to become a fully-integrated oncology-focused biotech AstraZeneca obtains full oncology rights to monalizumab AstraZeneca gains access...

Confirmation of previously reported response rate and new data on durability of response reinforces the potential anti-tumor activity of the monalizumab cetuximab combination Clinical program advances...

IPH5401 is a first-in-class antibody targeting the C5a receptor expressed on subsets of myeloid-derived suppressor cells (MDSC) and neutrophils in the tumor microenvironment IPH5401 combined with PD-1...